Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director David R. Ebsworth Sells 1,904 Shares

Key Points

• Verona Pharma PLC Director David R. Ebsworth sold 1,904 shares at an average price of $13.14, totaling $25,018.56 in value, reducing his ownership by 0.22% to 880,499 shares.
• The stock has a market cap of $8.97 billion and has seen fluctuations between a twelve month low of $19.45 and a high of $105.50.
• Recent analyst ratings show a shift, with several brokerages downgrading the stock from "strong-buy" to "hold", with an average price target of $109.00.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) Director David R. Ebsworth sold 1,904 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $13.14, for a total value of $25,018.56. Following the sale, the director owned 880,499 shares of the company's stock, valued at approximately $11,569,756.86. This trade represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Verona Pharma PLC American Depositary Share Trading Down 0.1%

Shares of Verona Pharma PLC American Depositary Share stock traded down $0.12 during trading hours on Friday, hitting $105.28. The company's stock had a trading volume of 610,545 shares, compared to its average volume of 4,298,595. The stock has a market cap of $8.96 billion, a price-to-earnings ratio of -106.34 and a beta of 0.12. The company has a debt-to-equity ratio of 0.87, a quick ratio of 8.73 and a current ratio of 10.71. Verona Pharma PLC American Depositary Share has a twelve month low of $21.56 and a twelve month high of $105.50. The firm has a fifty day moving average of $97.20 and a 200-day moving average of $75.53.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.14. The firm had revenue of $103.14 million for the quarter, compared to analyst estimates of $90.41 million. Verona Pharma PLC American Depositary Share had a negative net margin of 36.62% and a negative return on equity of 21.12%. Research analysts forecast that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current year.

Institutional Investors Weigh In On Verona Pharma PLC American Depositary Share

Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its position in shares of Verona Pharma PLC American Depositary Share by 5.6% during the second quarter. GAMMA Investing LLC now owns 1,940 shares of the company's stock worth $183,000 after purchasing an additional 103 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in Verona Pharma PLC American Depositary Share by 44.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock worth $40,000 after buying an additional 193 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in Verona Pharma PLC American Depositary Share by 4.6% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,675 shares of the company's stock worth $442,000 after buying an additional 205 shares during the period. Townsquare Capital LLC lifted its holdings in Verona Pharma PLC American Depositary Share by 1.9% during the 4th quarter. Townsquare Capital LLC now owns 17,958 shares of the company's stock worth $834,000 after buying an additional 332 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Verona Pharma PLC American Depositary Share by 3.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,880 shares of the company's stock valued at $1,124,000 after purchasing an additional 394 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on VRNA. BTIG Research cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 10th. Wolfe Research lowered shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 10th. Truist Financial cut Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Wednesday, July 9th. Canaccord Genuity Group downgraded Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and set a $107.00 price objective on the stock. in a research report on Wednesday, July 9th. Finally, Wells Fargo & Company lowered Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and lowered their price objective for the stock from $138.00 to $107.00 in a research note on Thursday, July 10th. Eleven investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $109.00.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.